Drug Combination Details
| General Information of the Combination (ID: C63570) | |||||
|---|---|---|---|---|---|
| Name | Gambogic acid NP Info | + | Gefitinib Drug Info | ||
| Structure |
|
+ |
|
||
| Disease |
Lung cancer
[ICD-11: 2C25]
|
Investigative | [1] | ||
| Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
|---|---|---|---|---|---|---|
| α. Reversing Drug Resistance by This Combination | ||||||
| Reversing Drug Resistance | Click to Show/Hide | |||||
| Experiment 1 Reporting the Effect of This Combination | [1] | |||||
| Molecule(s)
Regulation |
Down-regulation | Phosphorylation | AKT1 | Molecule Info |
Pathway MAP
|
|
| Up-regulation | Expression | BAX | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | BCL-2 | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Phosphorylation | ERK1 | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Phosphorylation | MEK1 | Molecule Info |
Pathway MAP
|
||
| In-vitro Model | NCI-H1975 | CVCL_1511 | Lung adenocarcinoma | Homo sapiens | ||
| In-vivo Model | The mice were subcutaneously injected with 1*107 NCI-H1975 cells suspended in 100 uL of Matrigel. | |||||
| Experimental
Result(s) |
Gefitinib in combination with GA resulted in antitumor growth in the EGFR-T790M secondary mutation NCI-H1975 tumor model due to an enhanced apoptotic effect. | |||||
| References | ||||
|---|---|---|---|---|
| Reference 1 | Combined therapy with EGFR TKI and gambogic acid for overcoming resistance in EGFR-T790M mutant lung cancer. Oncol Lett. 2015 Oct;10(4):2063-2066. | |||
